Domestic pharmaceutical companies are now focusing on the over-the-counter (OTC) segment to accelerate sales growth. They are relaunching older prescription brands in the space or taking an inorganic route to beat the slowdown in sales. The industry’s domestic pharmaceutical sales dipped to 5.5 per cent in 2017 — the lowest growth rate in eight years. Relaunching older prescription drugs in the OTC space allows companies to overcome sluggish prescription growth and also extend life of mature brands.
Over-the-counter route to accelerate sales growth for domestic pharma firms
Date posted: Tuesday 16 January 2018